The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
MOST POPULAR
